The New York Times (11/22, Schmall ) reported, “A company that makes clonazepam, a drug commonly prescribed for anxiety and seizures, has expanded its recall of some of the pills after it discovered that they were labeled with the wrong strength, the Food and Drug Administration announced.” According to the Times, “the company, Endo, recalled 16 product lots of clonazepam, a drug best known by the brand name Klonopin.” Endo “said it had not received any reports of adverse events related to the recall.”

Related Links: — “The New York Times (requires login and subscription)

Medical Economics (11/21, Littrell) reports, “More than one in five U.S. adults, which equates to 59.3 million people, were living with mental illnesses in 2022, yet just more than half of them (50.6%) had received treatment in the previous year.” A new study, from Gallup and West Health, “uncovered that 70% of Americans would prefer to be asked about both their physical health and their mental health during appointments with their primary care providers (PCPs).” The survey “reported that 65% of men and 76% of women hoped to discuss both physical and mental health with their PCPs.” The research “also found that 66% of U.S. adults have been asked about their mental health by their PCPs or family practitioners, whereas 32% of adults said that had never happened.”

Related Links:

— “70% of Americans want primary care providers to address mental health,” Austin Littrell, Medical Economics, November 21, 2024

Psychiatric News (11/21) reports “several studies have shown that individuals with a parent who died by suicide have an increased risk of suicide or self-harm themselves compared with individuals with living parents or a parent who died from other causes,” but a new study “now finds that this risk may be particularly elevated when the individual reaches the same age at which the parent died by suicide.” The researchers said, “Our findings support the idea of a dynamic process of grief, in so much as the elevated risk of suicidal behavior at [parental] age correspondence might also represent a period of loss orientation and increased distress.” The findings were published in Suicide and Life-Threatening Behavior.

Related Links:

— “Reaching Age at Which Parent Died by Suicide Increases Suicide Risk Among Offspring,” Psychiatric News, November 21, 2024

The New York Times (11/21, Hoffman , Weiland ) reports, “After years of relentless rises in overdose deaths, the United States has seen a remarkable reversal.” For seven consecutive “months, according to federal data, drug fatalities have been declining.” Expanded prevention, treatment, “and education efforts are playing a role, but drug policy experts believe there is another, surprising reason: changes in the drug supply itself, which are, in turn, influencing how people are using drugs.” For example, “the fentanyl on the street is starting to become weaker.” According to addiction experts, “other interventions contributed to the declining fatalities, including wider distribution of overdose reversal medications” and “an uptick in some states in prescriptions for medication that suppresses opioid cravings.”

CNN (11/21, McPhillips ) reports, “The US Drug Enforcement Administration says that less fentanyl is present in the nation’s illicit pill supply and that is helping drive down overdose deaths in the United States.” However, “experts say that there are limitations to this claim and that many other factors are probably playing a role.”

Related Links:

— “Less-potent fentanyl pills may be playing a role in decrease of US overdose deaths, DEA says,” Deidre McPhillips, CNN, November 21, 2024

Psychiatric News reports, “A panel convened by the Food and Drug Administration (FDA) voted overwhelmingly…against key provisions of the Clozapine Risk Evaluation and Mitigation Strategy (REMS) after hearing from clinicians, patients, and caregivers who said access to this effective schizophrenia medication was thwarted by red tape.” The FDA “panel voted 14-1 against the REMS requirement that prescribers document and pharmacies verify patients’ absolute neutrophil counts (ANC) before dispensing clozapine.” Additionally, the panel “voted 14-1 against the need for educating prescribers and pharmacists on the risk of clozapine-induced severe neutropenia and ANC monitoring.”

Related Links:

— “FDA Panel Votes 14-1 Against Clozapine REMS,” Psychiatric News, November20 , 2024